Amgen Cuts 300 In San Francisco

Thousand Oaks-based biotech Amgen is cutting 300 jobs in San Francisco, as part of a shutdown of the South San Francisco operations of subsidiary Onyx Pharmaceuticals, according to a memo leaked from the company on Tuesday. Amgen plans to transfer workers in San Francisco back to its Thousand Oaks headquarters. Amgen acquired Onyx Pharmaceuticals in 2013, in a $10.4 billion deal. Onyx Pharmaceuticals develops treatments for multiple myelomas.